Latest Innovation News

Many Peaks Minerals has reported significant drilling progress and new high-grade gold targets at its Côte d'Ivoire projects, supported by strong financial backing and strategic leadership appointments.

Green Technology Metals (ASX: GT1) secures a Letter of Interest for up to C$100 million financing from Export Development Canada, underpinning its Seymour Lithium Project and advancing drilling and development across its Ontario lithium hubs.

Race Oncology has advanced its Phase 1 clinical trial for RC220, submitting ethics approvals and bolstering its cash reserves to $18.78 million following a $5.25 million R&D tax incentive.

Venus Metals Corporation reports compelling gold assay results from its Henderson and Sandstone projects, alongside advancing mining lease applications and maintaining a robust cash position of $12.4 million.

ABx Group reports significant progress in its rare earths and bauxite ventures, including enhanced geological models and pilot plant developments supported by key partnerships and government backing.

Jatcorp Limited faces a sharp revenue drop due to a trademark dispute in China but accelerates growth with new Moroka® products and expanded distribution channels.

Nimy Resources advances its Mons Project with significant high-grade copper and gallium mineralisation confirmed at Masson and Block 3 East prospects, supported by a successful capital raise and a CSIRO research grant.

Optiscan Imaging Ltd reported a productive December quarter, marked by key product developments, strategic partnerships, and a stronger cash position, setting the stage for growth in medical and veterinary imaging markets.

Gratifii reports a remarkable 110% increase in 2Q FY25 cash receipts, driven by strategic acquisitions and strong client engagement, setting the stage for sustained growth and profitability in the coming quarters.

AdAlta Limited has bolstered its leadership team and progressed its 'East to West' cellular therapy strategy alongside its lead drug candidate AD-214, despite a tightening cash position. The company’s recent non-binding term sheet and new clinical data signal promising momentum in its biotech pipeline.

Imugene Limited reports durable patient responses in multiple cancer immunotherapy trials and strengthens its financial position with a $46 million convertible note deal and a substantial R&D tax refund.

Simonds Group has agreed to acquire Dennis Family Homes for $10 million, significantly expanding its residential construction footprint and product portfolio across Victoria and New South Wales. The acquisition is expected to be earnings accretive from the first quarter of FY26.